DVRG.L Regulatory News (DVRG)

31 March 2021

DeepVerge PLC

("DeepVerge" or "Company")

DeepVerge Investor Presentation

Project Updates on Labskin, Modern Water, Skin Trust Club

DeepVerge (LSE:DVRG.L), the environmental and life science AI company, is pleased to provide an update ahead of Gerry Brandon, the CEO of DeepVerge presentation relating to Project Updates - Labskin, Skin Trust Club, Modern Water - Wastewater & Breath Test via the Investor Meet Company platform on 31st Mar 2021 at 1:30pm BST.

· Incredibly busy period with continued growth across all business divisions:

§ FY 2020 unaudited - organic growth - £4.4m

§ FY 2020 aggregated revenues £6.1m (unaudited)

§ Dec 2020: Cash & Cash Equivalent £2.97m

§ Post Dec 2020: £650,740 in exercised warrants

· FY 2021 guidance remains at £10m with £3.6m already received in Modern Water orders in Q1

· The Labskin Division has sealed its reputation as a leading diagnostics partner with global partners and new service offerings

§ We work with 18 of the top 20 global pharma companies.

§ Virtual clinical trials with remote collection of human volunteer's skin microbiome

• New solution for the collection of volunteer microbiomes to allow for lab controlled clinical trials of advanced skin models (pigmented, acne, atopic dermatitis, psoriasis) and human microbiomes

• As the data bank of remote volunteers grow the higher the accuracy and increased reliability of virtual product testing can be provided to clients eliminating early human trial and error testing and faster time to market

• Building of a data repository to allow AI modelling of skin conditions and ingredient effects

§ Launch of Skin Trust Club Artificial Intelligent (A.I.) Skincare App and Home Test Kit

• 2,000 members in the Alpha test with more than 5,000 before we stopped accepting for the Beta of which we will throttle back to complete.

• Self-administered skin swab from home-test-kit allows the clinical trial or Skin Trust Club participant to conduct a simple test without interaction

• DNA test that generates a report consumers can use to manage their custom skincare regimen. Analysis of skin attributes provides information to create hundreds of different product combinations to suit a persons unique skin microbiome

• As the data bank of remote volunteers grow the higher the accuracy and increased reliability of virtual product testing can be provided to clients eliminating early human trial and error testing and faster time to market

· Environmental Health division also continues to grow apace with new equipment, solutions, labs and services creating a strong $5m (£3.7m) sales pipe for Microtox and Microtrace in Q1 alone:

§ New equipment rolling off production lines on three continents to meet demand across the Microtox and MicroTrace range with new range of real-time surveillance services in Water Quality Monitoring

§ New solutions to detect contaminants of concern and forever chemicals through Microsaic systems, mass spectroscopy-based identification systems and our work with the Aptamer Group

§ Two New Containment Level 3 (Virus) level labs at our York UK facility

§ New services to detect dangerous pathogens, including contagious infections as well as community detection of opioids

· Initial data from ongoing Phase III COVID-19 detection studies demonstrates ability to identify and detect the virus

§ Public Health England access to the SARS-CoV-2 virus at Category 3 lab with University of Aberdeen, Genoa, Italy and Liverpool University

• Identified the virus S-Protein in quantities at 40 femtogram per millilitre ("Fg/mL")

• Close to 100% sensitivity and specificity on DeepVerge's Microtox® BT nano-optofluidic chip

§ 40 subject breath test clinical trial concluded at Royal College of Surgeons, Ireland

• 16 independently confirmed as COVID-19 positive with PCR tests

• Breath samples were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group") and Optimers ("Aptamer Group")

• Detection of the live virus confirmed indicating 9 times increase in digital spectrum signal on the Microtox® BT compared to control

• Microtox® BT delivered results in under 60 seconds from breath samples

§ Subject to completion of additional human trials, the Microtox® BT would be expected to meet the criteria for UK, MHRA's Target Product Profile Rapid Breath Test which would enable us to roll out the COVID19 and other pathogen breath tests later this year

· 2021 looks to be a promising year for DeepVerge with progress ramping up and particularly strong interest from China for our Microtox products, as well as our new Labskin offerings.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet DEEPVERGE PLC via:

https://www.investormeetcompany.com/deepverge-plc/register-investor

Investors who already follow DEEPVERGE PLC on the Investor Meet Company platform will automatically be invited.

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments and the data they generate, for the analysis and identification of bacteria, virus and toxins. DeepVerge is utilising artificial intelligent data analytics to prove scientifically the impact of skincare product claims on the skin microbiome for clients including most of the top 20 global cosmetic companies and to detect remotely, and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.